PC
CYTK icon

Palo Capital’s Cytokinetics CYTK Stock Holding History

Palo Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17,285
Closed -$122K – 219
2016
Q1 		$122K Buy
17,285
+6,693
+63% +$48.9K 0.1% 165
2015
Q4 		$111K Buy
+10,592
New +$104K 0.1% 115
2015
Q3 		– Sell
-11,526
Closed -$77K – 135
2015
Q2 		$77K Buy
+11,526
New +$75.6K 0.06% 125

Other funds holding CYTK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Palo Capital's CYTK Position: Q2 2016 in Review

Palo Capital sold out of Cytokinetics (CYTK) in Q2 2016, closing a stake of 17,285 shares — an estimated $122K sold.

Palo Capital first reported a position in CYTK in Q2 2015 and held it in 3 quarters. The position peaked at $122K in Q1 2016. 95 funds tracked by Wall St. Rank hold CYTK as of Q2 2016.

  • Palo Capital reported no remaining Cytokinetics position as of Q2 2016 after selling out during the quarter.
  • Palo Capital sold 17,285 Cytokinetics shares in Q2 2016, an estimated $122K.
  • Palo Capital first reported a position in Cytokinetics in Q2 2015 and held it in 3 quarters.
  • Palo Capital's Cytokinetics position peaked at $122K in Q1 2016.
  • 95 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2016.

Based on Palo Capital's 13F filing for Q2 2016, filed 20 Jul 2016.